Redeye provides its initial take on Vitec’s Q1 2023 report, which came in broadly above our estimate...
Net sales SEK 476m, 3% vs ABGSCe Adj. EBITA SEK 64m, 4% vs ABGSCe On unrevised ests, share trading a...
Redeye concludes that Q1 was weaker than Redeye had estimated.
Redeye comments on Invisio ahead of its Q1 2023-results (due 4 May) where we expect continued strong...
Ahead of Cibus' Q1 report, we update our estimates (after our research restriction period ending) to...
Redeye raises its Base Case, forecasts, and Redeye Rating for ADDvise following a streak of solid re...
We cut '23e-'25e EBIT by 49-34% Easee ban weighs on EFUEL '23e-'24e EV/EBIT ~23x-10x What to expect ...
Q1e 36% org. growth, but limited margin improvement q-o-q We cut '23e-'24e adj.
Cut Q1'23e sales by 2% Resiliency due to high share of recurring revenue Long-term prospects intact
Tillväxtresan fortsätter in i 2023 men lönsamheten pressas under Q1.
Redeye comments on the recent news of satellite launches by Wyld Network’s partners, namely Eutelsat...
Intäkterna minskade under Q4 men den långsiktigt positiva utsikten är intakt.
Redeye comments on the new data presented by BioInvent from the intravenous arm of the study.
We initiate coverage of Agilyx with a fair value range of NOK 62-84.
EBITDA SEK 0m vs. ABGSCe SEK 2m Performance Chemicals weaker than expected, -7% growth y-o-y Confere...
Hansa’s Q1 is soft in terms of product sales. We expect 2023 recurring sales contributions to be squ...
Safeture reported a stable Q1 2023, showing clear signs of scalability and a healthy growth rate.
Consti reports its Q1 2023 earnings on 27th of April.
Solteq intends to divest its ERP business based on Microsoft BC and LS Retail solutions.
Redeye provides an update on Freemelt ahead of its Q1-results (due 10 May), where we lower our sales...
